Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000070.xml
Download PDF
Semin Musculoskelet Radiol 2013; 17(02): 168-176
DOI: 10.1055/s-0033-1343094
DOI: 10.1055/s-0033-1343094
Current Imaging and Therapy of Malignant Soft Tissue Tumors and Tumor-like Lesions
Further Information
Publication History
Publication Date:
14 May 2013 (online)
Abstract
Soft tissue tumors are histologically classified based on the tissue type they reflect. MR and computed tomography imaging remains the mainstay for the evaluation of a soft tissue mass including guiding the biopsy to the most aggressive portion of the lesion, tumor staging, and evaluating local recurrence and metastatic disease. Although some lesions may be readily identified based on their imaging characteristics, many soft tissue tumors remain indeterminate and require biopsy for diagnosis of histologic type and lesion grade, factors that have an impact on therapeutic options and long-term disease-free survival.
In this article we review the current literature regarding imaging and treatment of soft tissue lesions in the musculoskeletal system. Positron emission tomography and specialized MR techniques, such as spectroscopy and diffusion-weighted imaging, are useful in the diagnosis of high-grade soft tissue sarcomas, although imaging overlap exists with benign and low-grade sarcomas. These modalities are proving useful in primary tumor staging, evaluation of therapeutic response, and metastatic disease assessment. We also discuss the roles of percutaneous ablation in the treatment of focal disease and palliative pain control, and review current targeted cancer therapies.
-
References
- 1 Howlader N, Noone AM, Krapcho M , et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations), Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/ . Accessed July 7, 2012
- 2 Parsons HM, Habermann EB, Tuttle TM, Al-Refaie WB. Conditional survival of extremity soft-tissue sarcoma: results beyond the staging system. Cancer 2011; 117 (5) 1055-1060
- 3 Billingsley KG, Burt ME, Jara E , et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 1999; 229 (5) 602-610 ; discussion 610–612
- 4 Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66 (18) 8927-8930
- 5 Aoki J, Watanabe H, Shinozaki T , et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003; 32 (3) 133-138
- 6 Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003; 32 (4) 201-208
- 7 Ioannidis JPA, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003; 44 (5) 717-724
- 8 Lakkaraju A, Patel CN, Bradley KM, Scarsbrook AF. PET/CT in primary musculoskeletal tumours: a step forward. Eur Radiol 2010; 20 (12) 2959-2972
- 9 Ferner RE, Golding JF, Smith M , et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19 (2) 390-394
- 10 Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007; 245 (3) 839-847
- 11 Hamada K, Tomita Y, Ueda T , et al. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 2006; 20 (10) 671-675
- 12 Eilber FC, Rosen G, Eckardt J , et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19 (13) 3203-3209
- 13 Evilevitch V, Weber WA, Tap WD , et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008; 14 (3) 715-720
- 14 Schuetze SM, Rubin BP, Vernon C , et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005; 103 (2) 339-348
- 15 Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002; 179 (5) 1145-1150
- 16 Yanagawa T, Watanabe H, Inoue T , et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J Comput Assist Tomogr 2003; 27 (2) 175-182
- 17 Zhang H, Tian M, Oriuchi N , et al. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 2003; 24 (3) 273-279
- 18 Costa FM, Canella C, Gasparetto E. Advanced magnetic resonance imaging techniques in the evaluation of musculoskeletal tumors. Radiol Clin North Am 2011; 49 (6) 1325-1358 , vii–viii
- 19 Mirowitz SA, Totty WG, Lee JK. Characterization of musculoskeletal masses using dynamic Gd-DTPA enhanced spin-echo MRI. J Comput Assist Tomogr 1992; 16 (1) 120-125
- 20 van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC , et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology 2004; 233 (2) 493-502
- 21 Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol 2000; 34 (3) 229-246
- 22 Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol 2007; 11 (3) 240-245
- 23 Doganay S, Altinok T, Alkan A, Kahraman B, Karakas HM. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors. Eur J Radiol 2011; 79 (2) e33-e37
- 24 van Rijswijk CSP, Kunz P, Hogendoorn PCW, Taminiau AHM, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging 2002; 15 (3) 302-307
- 25 Einarsdóttir H, Karlsson M, Wejde J, Bauer HCF. Diffusion-weighted MRI of soft tissue tumours. Eur Radiol 2004; 14 (6) 959-963
- 26 Oka K, Yakushiji T, Sato H , et al. Ability of diffusion-weighted imaging for the
differential diagnosis between chronic expanding hematomas and malignant soft tissue
tumors. J Magn Reson Imaging 2008; 28 (5) 1195-1200
MissingFormLabel
- 27 Carrino JA, Khurana B, Ready JE, Silverman SG, Winalski CS. Magnetic resonance imaging-guided percutaneous biopsy of musculoskeletal lesions. J Bone Joint Surg Am 2007; 89 (10) 2179-2187
- 28 Wu HT, Chang CY, Chang H , et al. Magnetic resonance imaging guided biopsy of musculoskeletal lesions. J Chin Med Assoc 2012; 75 (4) 160-166
- 29 Nakamura T, Matsumine A, Yamakado K , et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas [corrected]. Cancer 2009; 115 (16) 3774-3781
- 30 Keil S, Bruners P, Brehmer B, Mahnken AH. Percutaneous radiofrequency ablation for treatment of recurrent retroperitoneal liposarcoma. Cardiovasc Intervent Radiol 2008; 31 (Suppl. 02) S213-S216
- 31 Shoji F, Taketomi A, Yano T, Maehara Y. Intraoperative radiofrequency ablation in an open thoracotomy setting for the new treatment of mediastinal liposarcoma: report of a case. Surg Today 2011; 41 (7) 992-994
- 32 Callstrom MR, Atwell TD, Charboneau JW , et al. Painful metastases involving bone: percutaneous image-guided cryoablation—prospective trial interim analysis. Radiology 2006; 241 (2) 572-580
- 33 van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18 (9) 1437-1449
- 34 Nair RT, vanSonnenberg E, Shankar S , et al. Visceral and soft-tissue tumors: radiofrequency and alcohol ablation for pain relief—initial experience. Radiology 2008; 248 (3) 1067-1076
- 35 Locklin JK, Mannes A, Berger A, Wood BJ. Palliation of soft tissue cancer pain with radiofrequency ablation. J Support Oncol 2004; 2 (5) 439-445
- 36 Ullrick SR, Hebert JJ, Davis KW. Cryoablation in the musculoskeletal system. Curr Probl Diagn Radiol 2008; 37 (1) 39-48
- 37 Malinowsky K, Wolff C, Gündisch S, Berg D, Becker KF. Targeted therapies in cancer—challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. J Cancer 2010; 2: 26-35
- 38 Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3 (1) 11-22
- 39 Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid organs. Oncologists 2007; 12 (12) 1443-1455
- 40 Wcislo G, Szarlej-Wcislo K, Szczylik C. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol 2007; 133 (8) 533-538
- 41 Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochemistry (Mosc) 2008; 73 (5) 605-618
- 42 Thomas D, Henshaw R, Skubitz K , et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11 (3) 275-280
- 43 Fenton ME, Jelinek JS, Salesky JS, Henshaw RM, Murphey MD. Findings of patients with giant cell tumor after treatment with Denosumab. Paper presented at: Annual Meeting of the International Society of Skeletal Radiology; September 2011; Coronado, CA
- 44 van der Graaf WT, Blay JY, Chawla SP , et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379 (9829) 1879-1886
- 45 McDonald ES, Yi ES, Wenger DE. Best cases from the AFIP: extraabdominal desmoid-type fibromatosis. Radiographics 2008; 28 (3) 901-906
- 46 Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17 (1) 158-167
- 47 Nuyttens JJ, Rust PF, Thomas Jr CR, Turrisi III AT. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 2000; 88 (7) 1517-1523
- 48 Romero JA, Kim EE, Kim CG, Chung WK, Isiklar I. Different biologic features of desmoid tumors in adult and juvenile patients: MR demonstration. J Comput Assist Tomogr 1995; 19 (5) 782-787
- 49 Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 100 (3) 612-620
- 50 Sturt NJ, Phillips RK, Clark SK. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 101 (3) 652 ; author reply 653
- 51 Ng TY, Yang MD, Chen YF, Chang CH. Resolution of hydronephrosis due to massive mesenteric fibromatosis using cyclo-oxygenase 2 inhibitors. Urology 2007; 70 (3) e3-e4
- 52 Morris LG, Sikora AG, Kuriakose MA, DeLacure MD. Tamoxifen therapy for aggressive fibromatosis of the posterior triangle of the neck. Otolaryngol Head Neck Surg 2007; 136 (4) 674-676
- 53 Stengel G, Metze D, Dörflinger B, Luger TA, Böhm M. Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon. J Am Acad Dermatol 2008; 59 (2, Suppl 1) S7-S9
- 54 Gega M, Yanagi H, Yoshikawa R , et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24 (1) 102-105
- 55 Azzarelli A, Gronchi A, Bertulli R , et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92 (5) 1259-1264